Abstracts tagged "dermatomyositis"

Abstract Number: 2172 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis
Nobuaki Ikeda, Yukie Yamaguchi, Miwa Kanaoka, Yasushi Ototake, Eriko Takebayashi and Michiko Aihara, Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Dermatomyositis (DM) is an autoimmune inflammatory disease characterized by skin eruptions and myositis, which is occasionally complicated by interstitial lung disease (ILD) or concomitant…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Juan J Maya, Olga Pinkston, Florentina Berianu, Benjamin Wang and Andy Abril, Rheumatology, Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…
Abstract Number: 1732 • 2017 ACR/ARHP Annual Meeting
The Characteristic T-Cell Receptor-Mediated Signaling of Peripheral Blood T Cells in Dermatomyositis and Polymyositis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: In dermatomyositis (DM) and polymyositis (PM), the characteristics of T cell expression in peripheral blood have been previously described; especially, decreased expression of interferon-γ…
Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Lavanya Mittal¹, Lingqiao Zhang², Rui Feng² and Victoria Werth¹, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…
Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 2130 • 2017 ACR/ARHP Annual Meeting
Joint Manifestations in Patients Diagnosed with Idiopathic Inflammatory Myopathy: Multicenter Registry on Inflammatory Myositis from the Rheumatology Society in Madrid, Spain
Larissa Valor¹, Diana Hernández-Flórez², Julia Martínez-Barrio³, Beatriz E. Joven⁴, Laura Nuño⁵, Carmen Larena⁶, Irene Llorente⁷, Carmen Barbadillo⁸, Paloma Garcia De La Peña⁹, Lucía Ruíz Gutiérrez¹⁰, Henry Moruno Cruz¹¹, Tatiana Cobo-Ibáñez¹², Raquel Almodóvar González¹³, Leticia Lojo¹⁴, MARIA JESUS GARCIA DE YEBENES Y PROUS¹⁵ and Francisco Javier López Longo¹⁶, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, ³Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Rheumatology, H.U. La Princesa, Madrid, Spain, ⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁹Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ¹⁰Pediatric Rheumathology Unit, University Children's Hospital Niño Jesús, Madrid, Spain, ¹¹University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹³Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario La Paz, Spain, Spain, ¹⁵Institute for Musculoskeletal Health, Madrid, Spain, ¹⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogeneous group of autoimmune conditions characterized by muscle non-suppurative inflammation, progressive muscle weakness and a variety of extra-muscular…
Abstract Number: 2132 • 2017 ACR/ARHP Annual Meeting
Angiogenesis and VEGF-Expressing Cells Are Identified Predominantly in the Fascia Rather Than the Muscle in the Early Phase of Dermatomyositis
Ken Yoshida^1,2, Haruyasu Ito¹, Kazuhiro Furuya¹, Taro Ukichi¹, Kentaro Noda¹ and Daitaro Kurosaka¹, ¹Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: We previously showed that fasciitis is a frequent manifestation of the disease in dermatomyositis (DM) but not in polymyositis (PM) and that DM-associated fasciitis…
Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Arya Kadakia¹, Amer Khojah², Gabrielle A. Morgan^3,4, Megan L. Curran⁵, Irwin Benuck⁶, Chinag-Ching Huang¹, Dong Xu⁷ and Lauren M. Pachman^8,9, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁴Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Pediatric Rheumatology, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Division of Cardiology, Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, IL, ⁷Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁸Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…
Abstract Number: 1376 • 2016 ACR/ARHP Annual Meeting
In Juvenile Dermatomyositis, Organ Damage Is Comparable after Median 13.5 and 21.5 Years Follow-up Time, Despite Sustained Disease Activity
Kristin Schjander Berntsen¹, Berit Flatø^1,2, Ivar Sjaastad^2,3 and Helga Sanner^1,4, ¹Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ²Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ³Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway, Oslo, Norway, ⁴Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway
Background/Purpose: All previous studies of disease outcome in juvenile dermatomyositis (JDM) patients have been based on retrospective data or cross sectional examination. We aimed to…
Abstract Number: 1500 • 2016 ACR/ARHP Annual Meeting
Concomitant Development of Interstitial Pneumonia Associated with Dermatomyositis and Rheumatoid Arthritis
Takeshi Shoda^1,2, Tohru Takeuchi³, Kentaro Isoda⁴, Takao Kiboshi⁴ and Shigeki Makino³, ¹Division of Clinical Immunology and Rheumatology, Osaka medical college, Osaka, Japan, ²Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan, ³Osaka medical college, Osaka, Japan, ⁴Yodogawa Christian Hospital, Osaka, Japan
Background/Purpose: A few cases of the concomitant development of interstitial pneumonia associated with dermatomyositis (DM-IP) and rheumatoid arthritis (RA) have been reported mainly in Asia,…
Abstract Number: 2103 • 2016 ACR/ARHP Annual Meeting
Peripheral Blood B Cells Are Expanded and Their Cytokine Expression Is Dysregulated in Juvenile Dermatomyositis
Meredyth Wilkinson¹, Christopher Piper², Georg Otto³, Claire Deakin⁴, Stefanie Dowle³, Stefania Simou⁵, Daniel Kelberman³, Yiannis Ioannou⁶, Claudia Mauri⁷, Elizabeth Jury⁸, David Isenberg⁹, Lucy R Wedderburn¹⁰ and Kiran Nistala¹¹, ¹Division of Medicine, University College London, London, United Kingdom, ²Rheumatology, University College London, London, United Kingdom, ³National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ⁴Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁷Division of Medicine, Centre for Rheumatology Research, University College London, University College London, London, United Kingdom, ⁸Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ⁹University College Hospital, London, London, United Kingdom, ¹⁰Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ¹¹Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare form of childhood autoimmune myositis that presents with proximal muscle weakness and heliotrope rash. B cells are strongly…
Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Gihyun Myung¹, Winnie Nelson² and Maureen A. McMahon³, ¹Division of Rheumatology/Department of Internal Medicine, University of California-Los Angeles, Los Angeles, CA, ²Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ, ³University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…
Abstract Number: 2311 • 2016 ACR/ARHP Annual Meeting
Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Shinji Sato¹, Kenichi Masui², Naoshi Nishina³, Yasushi Kawaguchi⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Kei Ikeda⁷, Takahiro Nunokawa⁸, Yoshinori Tanino⁹, Katsuaki Asakawa¹⁰, Yuko Kaneko¹¹, Takahisa Gono¹², Masataka Kuwana³ and JAMI investigators, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ¹⁰Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan
Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorder that affects muscle, skin and lung in various degree, and interstitial lung disease (ILD) is a…
Abstract Number: 2315 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Adam Schiffenbauer¹, Lisa G. Rider², Sara Faghihi-Kashani³, Komal Patel⁴ and Frederick W. Miller⁵, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Bethesda, MD, ⁵Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD
Background/Purpose: Clinical research is dependent on being able to recruit and enroll appropriate patients in sufficient numbers to make robust conclusions. For many diseases it…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].